Research into the anti-hyperglycemia activities of REAC on regulating the TLR4/NF-κB signaling pathway in STZ-induced diabetic mice showed that REAC (at daily doses of 300, 600, and 1,200 mg/kg, i.g. for 14 days) decreased the serum contents of fasting blood glucose (FBG), TNF-α, and IL-6 significantly and downregulated TLR4 and NF-κB protein and mRNA expressions in pancreatic tissue (Xu et al., 2015). Here, NFKB1 is linked to diabetes mellitus.